European Pharmaceutical Review

MARCH 13, 2023

Signing of the MOU “sets up Sandoz to expand patients’ access to the large number of biologics losing patent protection over the next few years,” commented Dominic Wake, Head of Market Access and Corporate Affairs at Sandoz. Full operations is provisionally planned for late 2026.

Networking 97

Networking Competition Pharma Pharmaceutical 97

pharmaphorum

OCTOBER 14, 2022

A consortium of industry and academic groups – led by Johnson & Johnson’s pharma division Janssen – has been set up to tackle the environmental impact of digital health products, specifically aimed at minimising waste that could end up in landfill. The project started on 1 October and is scheduled to complete in September 2026.

Leads 123

Leads Electronics Ethics Healthcare 123

pharmaphorum

JUNE 27, 2022

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. Ipsen’s CVR offer includes $0.30

Biopharma 100

Biopharma Sales Prescription FDA 100

European Pharmaceutical Review

MAY 25, 2023

Tara Dougal, Content Director of Pharma at Informa explained that each category in 2024 Exhibitor Awards “requires an implicit sustainability focus, we hope to encourage pharma companies and product developers to consider sustainability and environmental impact at each stage of the development process”.

Pharma 95

Pharma Distribution Pharmaceutical Patients 95

pharmaphorum

AUGUST 5, 2022

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world’s second-largest pharma market.

Side effects 92

Side effects Marketing Pharma Medicine 92

PM360

APRIL 7, 2023

Reduced patient out-of-pocket (OOP) costs in Part D have the potential to reduce beneficiary reliance on foundation support, with commensurate reductions in manufacturer donations required. The business-to-business market leaders must find new and creative ways to help patients receive their treatments. The 340B battle will rage on.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

Pharmaceutical Technology

APRIL 10, 2023

India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands. Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026.

Manufacturing 52

Manufacturing Medicine Sales Pharma 52

pharmaphorum

JANUARY 18, 2023

NewAmsterdam Pharma’s bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib. That means obicetrapib/ezetimibe could offer an affordable and patient-friendly alternative for patients with statin resistance.

Pharma 59

Pharma Prospecting Patients Safety 59

pharmaphorum

JANUARY 29, 2023

While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. In pharma, for instance, the global top 20 companies accounted for only about 35% market share in 1981, yet this figure had jumped to 65% by 2022.

Healthcare 94

Healthcare Healthcare Manufacturing Marketing 94

pharmaphorum

JULY 26, 2022

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candidate – oral CETP inhibitor obicetrapib. Remember CETP? Amgen licensed the rights to NewAmsterdam in 2020.

Side effects 52

Side effects Safety Pharma Patients 52

Pharma Marketing Network

MAY 12, 2021

Billion by 2026 with a CAGR of 37.2% The COVID-19 pandemic seriously accelerated the adoption and implementation of telehealth services, like remote patient monitoring and out-of-office “visits” – a trend that was already on the incline. And what are the implications to patients and providers? over the Forecast Period.”.

Physicians 59

Physicians Patients Safety Marketing 59

pharmaphorum

NOVEMBER 25, 2022

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan’s Kyowa Kirin, which are currently sold by affiliate companies across Europe.

Medicine 52

Medicine Marketing Pharma Management 52

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. 1 We have been improving patient affordability for over a decade, across generic and brand medications, including specialty treatments—sometimes by more than 50%.

Prescription 52

Prescription Medical Patients Distribution 52

pharmaphorum

DECEMBER 21, 2022

The deal doesn’t include the follow-up to a prostate-specific membrane antigen (PSMA) directed prostate cancer therapy that was abandoned last year after two patient deaths linked to neurotoxicity, which will be spun out along with another solid tumour programme targeting prostate stem cell antigen (PSCA).

Pharma 52

Pharma Manufacturing Engineering Safety 52

pharmaphorum

SEPTEMBER 23, 2022

Chances of FDA approval for Spectrum Pharma’s lung cancer candidate poziotinib and Oncopeptides’ Pepaxto for multiple myeloma have taken a dive, after the regulator’s expert advisors voted that the drugs were not ready to reach the market. Shares in the company were down 27% in after-hours trading.

FDA 52

FDA Patients Marketing Recruitment 52

Clarivate

APRIL 24, 2023

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients. Key acquisitions by U.S. healthcare organizations Company Founded Type No.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

pharmaphorum

OCTOBER 18, 2022

per share – values Akouos at $487 million and includes another $3 per share in a contingent value right (CVR) ties to the enrolment of patients into the gene therapy company’s clinical trials. The buyout – for $12.50 There are no approved drug treatments for this type of hearing loss.

Medicine 52

Medicine FDA Patients Pharma 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. Launch opportunity is reduced.

Doctors 59

Doctors Medicine Marketing Sales 59

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. starting new lung cancer patients on LIBTAYO® or melanoma patients on Opdualag instead of KEYTRUDA®).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare. But] frankly I’ve felt for a long time we [at the FDA] didn’t hold down the other part of the bargain.

FDA 52

FDA Prescription Medicine Biopharma 52

PM360

FEBRUARY 1, 2024

When asked about the clinical trial challenges they face, respondents said clinical trials are extremely costly, require significant expertise and coordination, are the most time-consuming element, patient recruitment, and it is difficult because of the law in different countries.

Recruitment 52

Recruitment Healthcare Healthcare Management 52

European Pharmaceutical Review

AUGUST 19, 2022

billion by 2026. In addition, investigators cited the increasing geriatric patient population, growing consumption of medicines, rising healthcare expenditure, improving healthcare infrastructure in emerging markets and mounting pressure to reduce healthcare costs as other factors driving market growth. Billion by 2026, achieving a 5.6

Manufacturing 98

Manufacturing Marketing Pharma Healthcare 98

pharmaphorum

DECEMBER 14, 2022

As many strive to bring about transformation in healthcare, Angelini Ventures takes a new approach to investments in digital health and life sciences companies that drive healthcare innovation and improve patient experiences. Serenis provides a unique platform that matches patients in need with certified therapists.

Healthcare 105

Healthcare Healthcare Patients Management 105

pharmaphorum

OCTOBER 27, 2022

Under the legislation, which has been slammed by pharma industry groups, Medicare pricing negotiations for some high-cost drugs would get underway in 2026, with drugmakers forced to pay rebates if prices rise faster than inflation.

Government 52

Government Insurance Safety Manufacturing 52

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

World of DTC Marketing

JULY 28, 2022

Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. Still, the pharma industry is fighting hard to keep it off the table. Pharma is a very profitable industry. The secretary of the U.S.

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

Clarivate

OCTOBER 17, 2024

There are two ways telehealth waivers can be extended through 2025 – via The Centers for Medicare & Medicaid Rule and legislatively through 2026 via H.R. Waivers enable access to medications for hundreds of thousands of patients nationwide for a variety of medical diagnoses including substance use disorder. As of Aug.

Healthcare 52

Healthcare Healthcare Government Insurance 52